Asset Details
Do you wish to reserve the book?
Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE ® against aerosolized rabbitpox virus in a rabbit model
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE ® against aerosolized rabbitpox virus in a rabbit model
Do you wish to request the book?
Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE ® against aerosolized rabbitpox virus in a rabbit model
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE ® against aerosolized rabbitpox virus in a rabbit model
2009
Overview
Infection of rabbits with aerosolized rabbitpox virus (RPXV) produces a disease similar to monkeypox and smallpox in humans and provides a valuable, informative model system to test medical countermeasures against orthopoxviruses. Due to the eradication of smallpox, the evaluation of the efficacy of new-generation smallpox vaccines depends on relevant well-developed animal studies for vaccine licensure. In this study, we tested the efficacy of IMVAMUNE
® [modified vaccinia Ankara-Bavarian Nordic (MVA-BN
®)] for protecting rabbits against aerosolized RPXV. Rabbits were vaccinated with either phosphate-buffered saline (PBS), Dryvax
®, a single low dose of IMVAMUNE
®, a single high dose of IMVAMUNE
®, or twice with a high dose of IMVAMUNE
®. Aerosol challenge with a lethal dose of RPXV was performed 4 weeks after the last vaccination. All PBS control animals succumbed to the disease or were euthanized because of the disease within 7 days postexposure. The rabbits vaccinated with Dryvax
®, a low dose of IMVAMUNE
®, or a single high dose of IMVAMUNE
® showed minimal to moderate clinical signs of the disease, but all survived the challenge. The only clinical sign displayed by rabbits that had been vaccinated twice with a high dose of IMVAMUNE
® was mild transient anorexia in just two out of eight rabbits. This study shows that IMVAMUNE
® can be a very effective vaccine against aerosolized RPXV.
Publisher
Elsevier Ltd,Elsevier,Elsevier Limited
Subject
/ Animals
/ Biological and medical sciences
/ Disease
/ Enzyme-Linked Immunosorbent Assay
/ Female
/ Fundamental and applied biological sciences. Psychology
/ IMVAMUNE
/ MVA
/ Rabbits
/ Smallpox
/ Smallpox Vaccine - immunology
/ Studies
/ Vaccines
/ Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
/ Vaccines, Attenuated - immunology
/ Vaccinia - prevention & control
/ Virology
